Oncolytics Biotech, Inc (ONCY) concluded trading on Thursday at a closing price of $0.58, with 3.73 million shares of worth about $2.16 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -34.44% during that period and on June 12, 2025 the price saw a gain of about 0.75%. Currently the company’s common shares owned by public are about 86.42M shares, out of which, 85.97M shares are available for trading.
Stock saw a price change of 73.35% in past 5 days and over the past one month there was a price change of 8.03%. Year-to-date (YTD), ONCY shares are showing a performance of -36.87% which decreased to -43.44% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.33 but also hit the highest price of $1.53 during that period. The average intraday trading volume for Oncolytics Biotech, Inc shares is 558.13K. The stock is currently trading 38.85% above its 20-day simple moving average (SMA20), while that difference is up 16.66% for SMA50 and it goes to -27.57% lower than SMA200.
Oncolytics Biotech, Inc (NASDAQ: ONCY) currently have 86.42M outstanding shares and institutions hold larger chunk of about 10.75% of that.
The stock has a current market capitalization of $51.24M and its 3Y-monthly beta is at 0.75. It has posted earnings per share of -$0.29 in the same period. It has Quick Ratio of 3.21 while making debt-to-equity ratio of 0.15. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ONCY, volatility over the week remained 16.02% while standing at 9.31% over the month.
Stock’s fiscal year EPS is expected to rise by 4.14% while it is estimated to decrease by -0.56% in next year. EPS is likely to shrink at an annualized rate of 6.60% for next 5-years, compared to annual growth of 23.13% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on October 06, 2022 offering a Buy rating for the stock and assigned a target price of $3 to it. Coverage by H.C. Wainwright stated Oncolytics Biotech, Inc (ONCY) stock as a Buy in their note to investors on February 17, 2021, suggesting a price target of $15 for the stock.
